Skip to main content

Advertisement

Table 2 Univariate Kaplan-Meier Survival Analysis according to different clinical characteristics and gene status of oncogenes and tumor suppressor genes from patients with CRC

From: Impact of genetic mutations and nutritional status on the survival of patients with colorectal cancer

  N Medium survival (months)
(CI 95%)
Log-rank p
Sex
 Male 12 36.4 (26.3–46.6) 0.450 0.502
 Female 34 42.1 (35.8–48.4)
Age
  < 60 years 18 47.4 (40.5–54.3) 3.286 0.070
  ≥ 60 years 28 33.9 (27.6–40.2)
Stage I / II / III 28 44.2 (37.8–50.6) 0.669  
IV 18 31.8 (24.0–39.6)   0.413
Tumor site
 Ascending and transverse colon 15 35.9 (27.1–44.7)   
 Descending and sigmoid colon 16 42.9 (33.4–52.5) 0.464 0.142
 Rectum 15 36.5 (30.0–43.0)   
Gene PIK3CA Wild type 14 42.6 (34.4–50.8) 0.936 0.333
Mutated 15 33.9 (25.5–43.4)
Gene KRAS
 Wild type 15 43.3 (35.7–50.9) 1.797 0.180
 Mutated 19 33.5 (25.5–41.5)
Gene NRAS
 Wild type 24 38.5 (31.4–45.6) 0.251 0.617
 Mutated 5 39.0 (24.6–53.4)   
Gene BRAF
 Wild type 24 38.2 (31.0–45.5) 0.426 0.514
 Mutated 5 39.8 (26.7–52.8)   
Gene EGFR
 Wild type 5 28.8 (22.6–35.1) 0.149 0.700
 Mutated 24 38.5 (31.3–45.8)   
Gene APC
 Wild type 13 44.5 (36.7–52.3) 1.983 0.159
 Mutated 16 32.6 (23.8–41.3)
Gene PTEN
 Wild type 21 38.3 (30.6–46.0) 0.257 0.612
 Mutated 8 38.1 (27.2–49.0)
Gene SMAD4
 Wild type 20 40.9 (33.4–48.4) 0.649 0.421
 Mutated 9 38.1 (22.2–45.0)
Gene FBXW7
 Wild type 19 39.3 (31.5–47.0) 0.007 0.934
 Mutated 10 35.8 (25.0–46.6)
Total mutations (Oncogenes and Tumor Suppressors)
  < 5 mutations 20 41.0 (33.5–48.4) 0.649 0.421
  > 5 mutations 9 33.6 (22.2–45.0)
  1. CI Confidence interval